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Abstract
Background—Elevated plasma fibrinogen associates with arterial thrombosis in humans and
promotes thrombosis in mice by increasing fibrin formation and thrombus fibrin content.
Fibrinogen is composed of six polypeptide chains: (Aα, Bβ, and γ)2. Alternative splicing of the γ
chain leads to a dominant form (γA/γA) and a minor species (γA/γ’). Epidemiologic studies have
detected elevated γA/γ’ fibrinogen in patients with arterial thrombosis, suggesting this isoform
promotes thrombosis. However, in vitro data show that γA/γ’ is anticoagulant due to its ability to
sequester thrombin, and suggest its expression is upregulated in response to inflammatory
processes.
Objective—To determine whether γA/γ’ fibrinogen is prothrombotic in vivo.
Methods—We separated γA/γA and γA/γ’ fibrinogen from human plasma-purified fibrinogen
and determined effects on in vitro plasma clot formation, and in vivo thrombus formation and
circulating thrombin-antithrombin complexes in mice.
Results and Conclusions—Both γA/γA and γA/γ’ fibrinogen were cleaved by murine and
human thrombin and were incorporated into murine and human clots. When γA/γA or γA/γ’ was
spiked into plasma, γA/γA increased the fibrin formation rate to a greater extent than γA/γ’. In
mice, compared to controls, γA/γA infusion shortened the time to carotid artery occlusion,
whereas γA/γ’ infusion did not. Additionally, γA/γ’ infusion led to lower levels of plasma
thrombin-antithrombin complexes following arterial injury, whereas γA/γA infusion did not.
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These data suggest that γA/γ’ binds thrombin in vivo, and decreases prothrombotic activity.
Together, these findings indicate that elevated levels of γA/γA fibrinogen promote arterial
thrombosis in vivo, whereas γA/γ’ does not.
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INTRODUCTION
Fibrinogen is a 340 kDa glycoprotein that circulates in plasma at 2–4 mg/mL, but during
acute inflammation can exceed 7 mg/mL. Fibrinogen is composed of two sets of three
polypeptide chains: Aα, Bβ, and γ. Alternative splicing of the main γA chain leads to the γ’
chain. Molecules containing the γ’ chain circulate as a heterodimer with the γA chain (2Aα,
2Bβ, and γA/ γ’) and comprise 8–15% of total fibrinogen in healthy individuals [1, 2].
Elevated fibrinogen levels are associated with increased risk of arterial thrombosis [3–5],
and we previously showed that when mice are infused with unfractionated human fibrinogen
(~90% γA/γA and 10% γA/γ’) and subjected to FeCl3-mediated carotid artery injury,
elevated plasma fibrinogen shortens the time to vessel occlusion [6]. These findings suggest
elevated fibrinogen is a causative, etiologic agent in arterial thrombosis. However, the
specific contributions of γA/γA and γA/γ’ fibrinogen isoforms to thrombosis in vivo are
unknown.
In vitro studies to define the biochemical role of the γ’ chain have shown that clots made
with purified γA/γ’ fibrinogen polymerize at a slower rate than clots made with purified
γA/γA fibrinogen [7]. Additionally, the γ’ chain supports high affinity binding to thrombin
exosite II [8, 9], and studies have shown that thrombin binding to the γ’ chain competitively
inhibits thrombin-mediated platelet activation [10] and reduces thrombin-mediated FpB
cleavage [7], and factor VIII [11] and V [12] activation. These properties suggest γA/γ’
fibrinogen has anticoagulant activity in vitro. Conversely, the γ’ chain does not inhibit
thrombin-mediated cleavage of FpA [7, 13], and has been reported to support higher affinity
binding of FXIII than the γA chain [14], although more recent studies suggest only slightly
tighter [14], or even similar [15], binding of FXIII to the γA/γ’ isoform compared to the
γA/γA isoform. Additional studies in purified systems report contradictory effects of the γ’
chain on clot structure and mechanical properties, demonstrating that the γ’ chain induces
the formation of alternately smaller [7, 13, 16] or larger [17] pores, and stiffer [18] or less
stiff [17] clots. These conflicting observations make it difficult to predict the role of γA/γ’
fibrinogen under physiologic conditions in thrombosis in vivo.
The role of the human γ’ chain in thrombosis has previously been tested in two in vivo
studies. Since the murine γ’ chain does not contain the thrombin-binding sequence found on
the human γ’ chain, Mossesson et al. developed a transgenic mouse that replaced the murine
γ’ chain with the human γ’ chain [19]. Following electrolytic injury to the femoral vein,
there was no difference in thrombus volume between mice containing the human γ’ chain
and wild type (WT) controls, although the presence of the human γ’ chain reduced thrombus
volume in mice that were also heterozygous for the factor V Leiden mutation [19].
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However, interpretation of these findings is complicated by the higher total fibrinogen in
WT mice compared to mice expressing the human γ’ chain. In a baboon model in which an
arteriovenous shunt was placed between the femoral artery and vein, an 18 amino acid
peptide mimicking the γ’ chain C-terminus (γ’ 410–427) inhibited fibrin-rich thrombus
formation [11]. These studies suggest the γ’ chain reduces fibrin accumulation and is
antithrombotic during venous thrombosis.
Given these findings, it is interesting that retrospective epidemiological studies have
correlated elevated γA/γ’ fibrinogen levels with increased incidence of coronary artery
disease [20], myocardial infarction [21], and stroke [22–24]. In particular, the finding that
some patients have an increased γ’-to-total fibrinogen ratio [22–25] indicates γA/γ’
fibrinogen is not merely a biomarker of increased total fibrinogen, and suggests a specific
role for γA/γ’ in arterial thrombosis. However, these studies do not and cannot demonstrate
causality of γ’ chain-containing fibrinogen in thrombosis. The objective of our study was to
determine the contribution of γA/γA and γA/γ’ fibrinogen to arterial thrombosis.
METHODS
Proteins and Materials
Polyclonal rabbit anti-human fibrinogen antibody was from DAKOCytomation (Carpinteria,
CA). Monoclonal anti-fibrin(ogen) antibody (59D8) was a generous gift of Drs. Marschall
Runge (University of North Carolina [UNC]), Charles Esmon (Oklahoma College of
Medicine), and Rodney Camire (University of Pennsylvania). Mouse anti-human γ’ chain-
specific antibody (2.G2.H9) was from Millipore (Temecula, CA). Biotinylated secondary
antibodies were from Vector Laboratories (Burlingame, CA). The AlexaFluor-488 protein
labeling kit and 10% pre-cast Tris-glycine gels were from Invitrogen (Carlsbad, CA).
Human α-thrombin and murine thrombin were from Enzyme Research Laboratories (South
Bend, IN). Lipidated tissue factor (TF, Innovin) was from Siemens (Newark, DE).
Phospholipid vesicles (phosphatidylserine/phosphatidylcholine/phosphatidylethanolamine)
were prepared as described [26]. Bovine serum albumin was from Sigma-Aldrich (St. Louis,
MO). Peroxidase substrate was from KPL (Gaithersburg, MD).
Plasma preparation
Contact-inhibited human normal pooled plasma (hNPP) was prepared from 40 healthy
subjects (50% female, 68% nonwhite) as described [27], in a protocol approved by the UNC
Institutional Review Board. γA/γ’ fibrinogen levels in hNPP were measured by ELISA, as
described [28]. Murine normal pooled plasma (mNPP) was prepared by collecting blood
from 49 female C57Bl/6 mice by inferior vena cava (IVC) venipuncture into 3.2% sodium
citrate (1:9 ratio sodium citrate:blood). Pooled whole blood was centrifuged (4000xg, 20
minutes), and platelet-poor plasma was aliquoted and frozen at −80°C.
Isolation of γA/γA and γA/γ’ fibrinogen
The γA/γA and γA/γ’ fibrinogen variants were separated from human plasminogen-, von
Willebrand Factor-, and fibronectin-depleted human fibrinogen (Enzyme Research
Laboratories Ltd., Swansea, UK), based on the method described previously [7]. After
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purification, variants were concentrated using Vivaspin 20 MWCO 100,000 columns (GE
Healthcare, Uppsala, Sweden) and dialyzed into 20 mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (pH 7.4) containing 150 mM NaCl (HBS). Fibrinogen concentration was
determined by absorbance at 280 nm using an extinction coefficient of 1.51 mL/(mg/cm).
Both variants were functionally active (>95%) in a standard clotability assay.
SDS-PAGE and western blotting
Fibrinogen preparations were assessed by 10% SDS-PAGE and Coomassie Brilliant Blue
staining or western blotting for total fibrinogen or fibrinogen γ’ chain. For western blots,
membranes were blocked with Tris-buffered saline with 1% Tween containing 5% milk,
washed, and probed sequentially with mouse-anti human γ’-specific primary antibody and
AlexaFluor-488 conjugated anti-mouse secondary antibody. Fluorescent signal was detected
on a Typhoon 900 FLA fluorescent scanner.
Clot formation with purified fibrin(ogen)
Purified fibrinogen, thrombin, and CaCl2 (0.5 mg/mL, 5 nM, and 10 mM, final,
respectively) were combined in 96-half-well plates and polymerization was monitored by
turbidity at 405 nm using SpectraMax Plus340 plate reader (Molecular Devices, Sunnyvale,
CA).
Clot formation in plasma
hNPP or mNPP was spiked with HBS (Control), or γA/γA or γA/γ’ fibrinogen, and clotting
was initiated with TF (1:30,000 dilution of Innovin, final), 10 mM CaCl2, and 4 µM
phospholipid vesicles in 96-well plates. Clot formation was monitored by turbidity at 405
nm.
Intravital microscopy
Procedures were approved by the UNC Institutional Animal Care and Use Committee.
Laser-induced thrombosis to cremaster muscle venules was performed as described [29].
Briefly, 6–8 week old male C57Bl/6 mice (Charles River Laboratories, Wilmington, MA)
were anesthetized and laser injuries were induced with an Ablate! photoablation system
equipped with an attenuatable 532 nm pulse laser (Intelligent Imaging Innovations). Five
minutes before injury, mice were injected via the retro-orbital plexus with AlexaFluor 595-
labeled anti-glycoprotein IX antibody (0.3 mg/g body weight; Emfret, Eibelstadt, Germany),
and AlexaFluor 647-labeled murine anti-fibrin antibody (0.2 mg/g body weight), and trace
amounts (5% of total fibrinogen) of AlexaFluor 488-labeled γA/γA or γA/γ’ fibrinogen. Five
venules maximum were studied per mouse.
FeCl3 thrombosis model
FeCl3 injury to carotid arteries was performed as described [6]. Briefly, 6–8 week old male
C57Bl/6 mice were anesthetized, and human fibrinogen or vehicle (HBS) was administered
through the left saphenous vein cannula on a per-weight basis 5 minutes before injury. The
right common carotid artery was exposed, dried and treated with FeCl3 (10% on 0.5×1.0-
mm filter paper) for 2 minutes. We specifically titrated the conditions to perform these
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experiments at a threshold at which some mice do not form thrombi, to allow for sensitivity
to both increased and decreased procoagulant activity. Blood flow was monitored by
Doppler ultrasonic flow probe, and the time to occlusion (TTO) was defined as the time
between FeCl3 administration and lack of flow for 60 consecutive seconds, as previously
described [6].
Measurement of circulating TAT complexes
TAT levels were measured by ELISA (Enzygnost TAT micro ELISA, Siemens) using
plasma prepared from IVC blood draws from mice subject to FeCl3 carotid artery
thrombosis. Samples showing hemolysis were excluded.
Statistical Methods
Descriptive statistics (mean, median, standard deviation [SD], standard error of the mean
[SEM]) were calculated. Groups were compared using Student’s t-tests (normally-
distributed data determined by Lilliefors test for normality) or Wilcoxon-Mann-Whitney
Rank Sum Tests (non-normally distributed data) in Kaleidagraph v4.1.3. Correlations were
performed using SAS 9.2 (SAS Inc., Cary, NC). P<0.05 was considered statistically
significant.
RESULTS
γA/γA fibrinogen increases the fibrin polymerization rate to a greater extent than γA/γ’
fibrinogen
Purified γA/γA fibrinogen contained all three fibrinogen chains (Aα, Bβ, and γ) at expected
molecular weights (Figures 1A-B). No γ’ chain was detected in γA/γA fibrinogen (Figure
1C), whereas purified γA/γ’ fibrinogen showed equal intensities of γA and γ’ bands (Figures
1A–B). We first clotted purified fibrinogens with purified human thrombin and followed
clotting by turbidity. Although fibrinogen γA/γA and γA/γ’ isoforms were not explicitly
depleted of FXIII, Allen et al. previously showed that the presence or absence of FXIII does
not affect differences in polymerization between γA/γA and γA/γ’ fibrinogen [17]. Indeed,
consistent with previous reports [7, 13, 17], purified γA/γA exhibited a faster polymerization
rate (2.7-fold, P<0.05) and higher final turbidity (1.5-fold, P<0.05) than purified γA/γ’
(Figure 1D, Table 1). Findings were similar when murine thrombin was used (Figure 1D,
Table 1), showing murine thrombin can convert human fibrinogen to fibrin.
To determine the effect of elevated γA/γA and γA/γ’ fibrinogen on plasma clot formation
during in situ thrombin generation, we spiked purified γA/γA, γA/γ’, or HBS (control) into
hNPP. The concentration of fibrinogen in hNPP was 3.1±0.1 mg/mL (100%) and baseline
concentration of γA/γ’ fibrinogen in hNPP was 0.42 mg/mL (13.5% of total fibrinogen). We
increased the total fibrinogen concentration to 3.5 (114%), 3.9 (127%), or 4.4 (143%)
mg/mL by spiking in purified γA/γA or γA/γ’, so that the γA/γ’-to-total fibrinogen ratios
ranged from 9.6–40.1% (Table 2). These levels span the range of γA/γ’ levels measured in
healthy individuals and patients with thrombosis [23–25, 30, 31]. Elevating either γA/γA or
γA/γ’ fibrinogen increased final clot turbidity compared to plasma spiked with HBS (Figure
2B, Table 2). When total fibrinogen was raised to 114%, neither γA/γA nor γA/γ’ fibrinogen
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increased the clot formation rate. However, elevating total fibrinogen to 127% or 143% with
γA/γA or γA/γ’ significantly and dose-dependently increased the clot formation rate versus
baseline (HBS). Notably, at each concentration, elevating total fibrinogen with γA/γA
increased the clot formation rate to a significantly greater extent than elevating total
fibrinogen with γA/γ’ (Figure 2C, Table 2). Linear regression analysis showed that the clot
formation rate correlated positively with elevated total fibrinogen (r=0.667, P<0.001) and
negatively with the γ’-to-total fibrinogen ratio (r=−0.0245, P=0.17), although the
relationship between γ’-to-total and clot formation rate did not reach significance. Moreover,
the level of γA/γA isoform correlated strongly with the clot formation rate (r=0.795,
P<0.001) whereas the level of γA/γ’ did not.
Spiking purified human γA/γA, γA/γ’, or HBS (Control) into mNPP produced similar
results. For these experiments, the fibrinogen concentration in mNPP was 2.4±0.2 mg/mL
(100%), and we spiked mNPP to 3.2 (135%) and 4.1 mg/mL (170%) with γA/γA or γA/γ’,
yielding human γ’-to total fibrinogen ratios ranging from 0–41.2%. Consistent with previous
observations [6], the final turbidity of murine plasma clots was lower than that of human
plasma clots, likely reflecting increased fibrin density of murine fibrin networks versus
human networks (unpublished observation). As in human plasma, both γA/γA and γA/γ'
increased the clot formation rate, but γA/γA increased the rate to a greater extent than γA/γ'
at each concentration tested (P<0.02, Figure 2F, Table 3). These findings suggest that during
in situ thrombin generation, both elevated γA/γA and γA/γ’ fibrinogen promote clot
formation, but γA/γA does so to a greater extent.
Both γA/γA and γA/γ’ fibrinogen are incorporated into murine thrombi in vivo
Drouet et al. previously suggested that an increased γ’-to-total fibrinogen ratio is detected in
patient plasmas because γA/γA is incorporated into platelet thrombi, whereas γA/γ’ is not
[25]. Therefore, we determined whether γA/γ’ was incorporated into thrombi in vivo. We
infused mice with AlexaFluor 594-labeled anti-platelet (anti-GPIX) antibody, AlexaFluor
647-labeled antibody against fibrin(ogen) (59D8), and trace amounts (5% of total
fibrinogen) of fluorescently-labeled γA/γA or γA/γ’ fibrinogen. We then triggered vascular
injury to the cremaster vessels and detected γA/γA or γA/γ’ fibrinogen within thrombi using
intravital microscopy. We initially performed this experiment with arterioles, but observed
substantial vessel constriction in response to the injury. However, the venule provided a
reasonable alternative that enabled us to avoid the issue of vasoconstriction while observing
platelet and fibrin(ogen) accumulation at the injury site in vivo. Figure 3 shows that both
γA/γA and γA/γ’ isoforms were incorporated into murine thrombi in vivo.
Following FeCl3 injury, γA/γA, but not γA/γ’, fibrinogen shortens the time to artery
occlusion
To determine the effect of elevated circulating γA/γA and γA/γ’ fibrinogen on arterial
thrombosis, we infused mice with HBS or purified human γA/γA, γA/γ’, or unfractionated
fibrinogen and induced thrombosis via FeCl3 application to the carotid artery. Both human
and mouse fibrinogen can be cleaved by human and murine thrombin, cross-linked by factor
XIIIa, and digested by plasmin [32]. Additionally, human fibrinogen circulates in mouse
plasma, and is incorporated into murine thrombi (Figure 1D, [6, 33–35]). For these
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experiments, we obtained total fibrinogen levels of 135% and 170% of normal levels, with
human-γ’-to-total fibrinogen ratios of 0%, 25.9%, and 41.2%, consistent with ratios found in
normal and pathological conditions [23–25, 30, 31, 36].
Consistent with previous findings, following FeCl3 injury, there was no significant
difference in TTO between control mice or mice infused to 135% mg/mL total fibrinogen
with either γA/γA or γA/γ’ (data not shown) [6]. When total fibrinogen was raised to 170%
with γA/γA fibrinogen, the median TTO was faster than that of mice infused with HBS
(5.48±0.50 versus 7.25±3.03 minutes [median±SEM], P<0.05, Figure 4A), similar to that
seen in mice infused with unfractionated fibrinogen. However, raising the level of
fibrinogen to 170% with γA/γ’ fibrinogen did not shorten the median TTO compared to
controls (Figure 4A). Moreover, 7.25 minutes after FeCl3 injury, 100% and 86% of mice
infused with unfractionated or γA/γA fibrinogen, respectively, had an occluded vessel,
whereas only 50% of mice infused with γA/γ’ fibrinogen developed vessel occlusion (Figure
4B). Together, these data indicate that elevated γA/γA fibrinogen promotes arterial
thrombosis, whereas elevated γA/γ’ does not.
Following FeCl3 injury, mice infused with γA/γ’ fibrinogen have lower circulating TAT
complexes than mice infused with γA/γA fibrinogen
The γ’ chain supports high affinity binding to thrombin exosite II [8, 9], and prior studies
have shown that γA/γ’ fibrinogen has anticoagulant properties (antithrombin I activity) in
vitro [10–12]. To determine the effect of γA/γ’ on procoagulant activity in vivo, we
measured TAT complexes in murine plasma following FeCl3 injury and stable vessel
occlusion. Whereas mice infused with unfractionated or γA/γA fibrinogen had similar
circulating TAT complexes as HBS-infused mice, mice infused with γA/γ’ had significantly
lower circulating TAT complexes (6.2±8.4 versus 18.9±10.9 ng/mL [median±SEM] for
γA/γ’ and HBS-infused mice, respectively, P<0.01, Figure 5), consistent with the concept
that thrombin binding to γA/γ’ fibrinogen sequesters thrombin [10–12, 37] and protects it
from inhibition by antithrombin. These findings suggest γA/γ’ fibrinogen binds and
sequesters thrombin in vivo and limits thrombin activity following vascular injury.
DISCUSSION
Although epidemiologic studies have associated elevated plasma fibrinogen with arterial
thrombosis [3–5], the operant pathogenic mechanisms have been controversial. We
previously showed that increased total plasma fibrinogen directly promotes arterial
thrombosis in mice [6]. Herein, we separately tested the role of γA/γA and γA/γ’ fibrinogen
and show that both elevated γA/γA and γA/γ’ increased the plasma clot formation rate, but
that γA/γA increased the rate to a greater extent than γA/γ’. Although both γA/γA and γA/γ’
fibrinogen were incorporated into murine clots, γA/γA fibrinogen shortened the TTO,
whereas γA/γ’ did not. Interestingly, compared to controls, mice infused with γA/γ’
fibrinogen had lower levels of circulating plasma TAT complexes following arterial injury,
whereas mice infused with γA/γA did not, suggesting that γA/γ’ fibrinogen binds and
sequesters thrombin in vivo. Together, our data indicate that γA/γ’ fibrinogen is not
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prothrombotic in vivo and may even have a protective role in preventing elevated total
fibrinogen levels from promoting thrombosis.
Our data support the premise that γA/γ’ fibrinogen has both procoagulant and anticoagulant
properties and exhibits both of these activities during thrombosis in vivo. Similar to γA/γA
fibrinogen, γA/γ’ increased the fibrin formation rate and final turbidity, though to a lesser
extent than γA/γA. Consequently, increased total fibrinogen levels, via either increased
γA/γA or γA/γ’, would be expected to promote fibrin formation. However, unlike γA/γA,
γA/γ’ fibrinogen exhibits antithrombin I activity in vitro [10–12, 37] and in vivo (Figure 5).
Thus, our finding that elevated γA/γA fibrinogen shortened the TTO, but elevated γA/γ’ did
not, suggests that the net effect of γA/γ’ fibrinogen’s opposing procoagulant and
anticoagulant activities yielded no change in the TTO. These data suggest that a peptide
representing the C-terminus of the γ’ chain would have strong anticoagulant effects in vivo,
since the procoagulant properties of the full length fibrinogen molecule would not be
present, whereas the thrombin binding properties of the γ’ chain would decrease circulating
thrombin. Indeed, this effect was previously demonstrated during in vivo thrombosis, in
which Lovely et al. saw decreased platelet and fibrin accumulation in the presence of γ’
chain peptide [11].
Although previous studies have compared isolated γA/γA and γA/γ’ fibrinogens in purified
systems, only one has done so during in situ thrombin generation in plasma. Using plasmas
from apparently healthy Black South Africans, Pieters et al. correlated total fibrinogen
levels, γA/γ’ fibrinogen levels, and the γ’-to-total fibrinogen ratio with the plasma clot
formation rate and turbidity change [38]. Their data suggest that the clot formation rate
increases with total fibrinogen, but decreases with elevated γ’-to-total fibrinogen ratio. Our
data extend these findings in a system that enabled us to precisely control fibrinogen isoform
levels and avoid variability between donor plasmas. Consistent with Pieters et al., we found
the clot formation rate correlated positively with elevated total fibrinogen. Importantly, the
level of γA/γA isoform correlated strongly with the clot formation rate, whereas the level of
γA/γ’ did not, suggesting the increase in clot formation rate caused by elevated total
fibrinogen is due to γA/γA fibrinogen.
Two prior studies evaluated the effect of the γ’ chain on thrombosis in vivo. Those studies
were limited by differences in the total fibrinogen level expressed by WT and human γ’-
expressing mice [19] and use of isolated γ’ peptide rather than full length γA/γ’ fibrinogen
[11]. Moreover, Mosesson et al. [19] evaluated γA/γ’ fibrinogen in a venous thrombosis
model, and although the arteriovenous shunt model used by Lovely et al. [11] included
aspects of arterial thrombosis, it did not recapitulate endothelial denudation and
subendothelial exposure associated with plaque rupture and arterial thrombus formation.
Consequently, our study supports and extends the prior findings in several important ways.
First, our infusion strategy enabled us to tightly-control the level of circulating γA/γA and
γA/γ’ fibrinogen, allowing us to specifically attribute effects to the levels of isoform and
total fibrinogen. Second, our study demonstrated the antithrombin I properties of the full-
length form of the γ’ chain. Third, our findings extend previous data from venous
thrombosis to arterial pathology. This extension is important since the role of γA/γ’ in
arterial thrombosis has been controversial. Our findings provide important evidence that
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γA/γA fibrinogen is causative in the etiology of arterial thrombosis, whereas γA/γ’
fibrinogen is not.
Given our findings showing that γA/γ’ fibrinogen does not promote arterial thrombosis, it
remains unclear why epidemiological studies find a positive association between elevated
γA/γ’ fibrinogen and arterial thrombosis. Previous studies have suggested that clots formed
from γA/γ’ fibrinogen are more resistant to lysis, and conflicting studies report abnormal
structure and mechanical stability in γ’-chain containing clots [7, 17, 18]. Thus, γA/γ’
fibrinogen may produce clots with increased stability that are detected because they persist
longer than clots that contain γA/γA. Interestingly, hypofibrinolysis is correlated with
increased risk of arterial thrombosis in young (<~50) [39, 40], but not older (>~50)
individuals [41, 42], suggesting abnormal clot stability explains some, but not all, of the
mechanisms leading to arterial thrombosis. Future studies are warranted to determine the
effect of the γA/γ’ isoform on arterial clot stability.
Interestingly, Rein-Smith et al. recently showed interleukin-6 preferentially up-regulates
hepatocyte production of γA/γ’ fibrinogen compared to γA/γA [43]. These data suggest
γA/γ’ (“antithrombin I”) expression is upregulated to limit endogenous procoagulant activity
triggered by inflammation. Indeed, C-reactive protein is elevated in patients with a history of
arterial thrombosis [23], reflecting the proinflammatory pathology. Increased γA/γ’ levels
detected in patients after arterial thrombosis are likely a consequence of disease rather than
cause, and reflect an innate, antithrombotic response to inflammation. Although our
fibrinogen infusion/acute thrombosis model enabled us to isolate and investigate the
immediate, direct effects of elevated γA/γA and γA/γ’ on thrombus formation, it did not
recapitulate the inflammatory process associated with atherosclerosis. Consequently, long-
term exposure to circulating γA/γ’ fibrinogen may have additional effects on plaque
formation and/or stability. Notably, however, Mosesson et al. did not report evidence of
chronic inflammation or atherosclerosis in their model of chronically-elevated fibrinogen γ’
levels [19] suggesting even chronic exposure to elevated γA/γ’ fibrinogen levels does not
cause thrombosis.
In summary, our results show that both γA/γA and γA/γ’ fibrinogen increased the fibrin
formation rate in plasma, but γA/γA fibrinogen accelerated the rate to a greater extent than
γA/γ’ fibrinogen. After arterial injury, γA/γA fibrinogen promoted thrombosis, whereas
γA/γ’ did not. Mice infused with γA/γ’ had lower levels of circulating TAT complexes,
suggesting that following vascular injury, γA/γ’ fibrinogen binds thrombin in vivo and limits
thrombin activity. Our data establish independent roles of fibrinogen γA/γA and γA/γ’ in
arterial thrombosis, and suggest γA/γA fibrinogen promotes thrombosis, whereas γA/γ’
sequesters thrombin and protects against procoagulant processes induced by inflammation.
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Figure 1. Purified fibrinogen contains all three chains (Aα, Bβ, and γA and/or γ’) at the expected
molecular weights and is equally cleaved by human and mouse thrombin
Unfractionated (UF), or purified γA/γA, or γA/γ’ fibrinogen were reduced and separated by
10% SDS-PAGE and detected by: A) Coomassie Brilliant Blue staining, B) polyclonal anti-
fibrin(ogen) antibody, or C) 2.G2.H9 antibody against the γ’ chain. D) Purified human
γA/γA (squares) or γA/γ’ (diamonds) fibrinogen was clotted in the presence of CaCl2 and
human (closed symbols) or murine (open symbols) thrombin. Data show mean±SD, for
experiments with human (n=3) and mouse (n=2) thrombin.
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Figure 2. Both γA/γA and γA/γ’ fibrinogen accelerate clotting in human and mouse plasma
A–C) hNPP was spiked with γA/γA or γA/γ’ to increase total fibrinogen to 114%, 127%, or
143% of normal (symbols appear in figure legend), and clot formation was triggered by
addition of TF and CaCl2. D-F) mNPP was spiked with human γA/γA or γA/γ’ to increase
total fibrinogen to 135% or 170% of normal (symbols appear in figure legend) and clot
formation was triggered by addition of TF and CaCl2. A, D) Polymerization was monitored
by turbidity; for clarity, only a subset of points is shown. B, C, E, F) The contribution of
increasing total fibrinogen with γA/γA (solid bars) or γA/γ’ (striped bars) on final turbidity
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(B, E) and fibrin formation rate (C, F) in human (B, C) and mouse (E, F) plasma. Dashed
lines represent final turbidity and clot formation rate of HBS controls. Data show means,
n=3. *p<0.05 versus HBS; #p<0.05 versus γA/γA.
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Figure 3. Intravital microscopy shows both γA/γA and γA/γ’ isoforms are incorporated into
murine thrombi
Venules were visualized in the cremaster muscle of mice infused with HBS (control) or
AlexaFluor 594-labeled anti-platelet (anti-GPIX) antibody, AlexaFluor 647-labeled anti-
fibrin antibody, and purified γA/γA or γA/γ’ directly labeled with AlexaFluor 488.
Thrombosis was triggered via laser injury. Flow is indicated by white arrows. Colors are:
platelets (red), fibrin(ogen) (green), and fibrin (blue). In the merged image, colors are:
platelets plus fibrin(ogen) (pink), platelets plus fibrin (purple), and fibrin(ogen) plus fibrin
(teal). Images show representative thrombi from 3–4 mice with 14–20 injuries total.
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Figure 4. γA/ γA fibrinogen shortens the time to vessel occlusion after arterial injury, but γA/γ’
does not
Mice were infused with HBS, unfractionated (UF), γA/γA, or γA/γ’ fibrinogen to 170%,
total fibrinogen. Thrombosis was induced by FeCl3 application to the carotid artery and
TTO was determined by Doppler flow probe. In vessels that did not occlude, the TTO was
recorded as 40 minutes. A) Each point represents a separate mouse. Lines indicate median
values, *p<0.05 versus HBS. B) Percent of mice occluded at 7.25 minutes (the median TTO
of HBS-infused mice), using the data from (A); 100%, 86%, and 50% of UF-, γA/γA-, and
γA/γ’-infused mice, respectively, had occluded vessels at this time.
Walton et al. Page 17






















Figure 5. Following arterial injury, mice infused with γA/γ’ fibrinogen have reduced circulating
TAT complexes
TAT levels were measured in plasmas collected from mice subjected to the FeCl3 carotid
artery thrombosis. Box plots indicate medians and upper and lower quartiles, *p<0.05 versus
HBS.
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